𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia

✍ Scribed by Wiseman, Gregory A.; Leigh, Bryan R.; Erwin, William D.; Sparks, Richard B.; Podoloff, Donald A.; Schilder, Russell J.; Bartlett, Nancy L.; Spies, Stewart M.; Grillo-López, Antonio J.; Witzig, Thomas E.; White, Christine A.

Book ID
121393352
Publisher
Mary Ann Liebert
Year
2003
Tongue
English
Weight
374 KB
Volume
18
Category
Article
ISSN
1084-9785

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 trial of fludarabine and mitox
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
✍ Pier Luigi Zinzani; Monica Tani; Stefano Fanti; Vittorio Stefoni; Gerardo Musura 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 1 views

## Abstract ## BACKGROUND A prospective, single‐arm, open‐label, nonrandomized Phase 2 study of combined fludarabine and mitoxantrone (FM) plus radioimmunotherapy was conducted to evaluate efficacy and safety in patients with untreated, indolent, nonfollicular non‐Hodgkin lymphoma (NHL). ## METHO

The city of hope experience with novel t
The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)
✍ A. Nademanee; H. Fung; A. Molina; A. Krishnan; R. Rodriguez; L. Popplewell; R.T. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 56 KB